Biostem Technologies Inc (BSEM) fair value: what the stock is really worth
As of Oct 12, 2026: fair value of Biostem Technologies Inc $3.73, price $2.44, upside +52.8%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range $0.5100 – $24.98 · fair‑value band $2.25 – $6.05 · the $2.44 price screens below the $3.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Biostem Technologies in your weekly email
Every Wednesday you see whether Biostem Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Show more
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Stock analysis
Biostem Technologies Inc (BSEM) currently trades at $2.44, while our model-based Fair Value estimate is $3.73, implying the stock looks roughly 34.5% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $33.99 per share, and 23 of the 24 models we run sit above the $2.44 price.
Bear case: the Asset-Based group reads lowest at $1.47, and 1 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: $2.25 (bear) to $6.05 (bull), the price of $2.44 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Biostem Technologies Inc reported revenue of $302M in FY2024 versus $2.5M in FY2020, a compound +230.8%/yr. Reported net income was $31.9M in FY2024.
Key figures
Market cap $57.3M · P/E ratio 2.8 · P/S ratio 0.29 · EPS (TTM) $0.8800 · Net margin 10.6% · Return on equity −74.7% · Return on assets (EBIT) −59.1% · Operating margin −106%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (medium confidence).
What moves the price
The share trades about 70% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 53%, BSEM screens cheaper than that median.
Fair Value models
Bear $2.25Fair Value $3.73Bull $6.05
Price $2.44 · Upside +52.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then ($0.8800 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,708.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+311.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+158.2%
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.3%
’10
’11
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−216.0% (2019) → 10.3% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Compare Biostem Technologies Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 593 stocks
Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score63 · Top 25%
Fair Value upside+52.8% · Top 25%
Profitability
Return on assets−18.1% · Below median
Net margin (TTM)−81.8% · Bottom 25%
Operating margin (TTM)−106.4% · Bottom 25%
Growth and dividend
Revenue growth−27.9% · Bottom 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Biostem Technologies Inc (BSEM) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of $3.73 versus a price of $2.44, about +53% upside (undervalued).
What is the fair value of BSEM?
Our model-based fair value for Biostem Technologies Inc is $3.73 (as of Oct 2, 2026), built from audited fundamentals. The current price: $2.44.
What is the quality score of BSEM?
Biostem Technologies Inc has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biostem Technologies Inc (BSEM)?
Our model-based price target is the fair value of $3.73 (as of Oct 2, 2026) from 24 valuation models. Cautious scenario $2.25, optimistic scenario $6.05. It is a calculation from audited fundamentals, not an analyst target.
What is the Biostem Technologies Inc stock forecast for 2026?
Our models put fair value at $3.73, about +53% upside versus a price of $2.44 (undervalued). Cautious scenario $2.25, optimistic scenario $6.05. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Biostem Technologies Inc (BSEM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biostem Technologies Inc it is $3.73 per share (as of Oct 2, 2026), against a price of $2.44. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Biostem Technologies Inc stock overvalued or undervalued in 2026?
As of Oct 2, 2026, BSEM trades below its calculated fair value: price $2.44, fair value $3.73, a gap of about +53% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BSEM?
No. The price is what the market pays today ($2.44); the fair value is what the company's own numbers justify ($3.73). For Biostem Technologies Inc the two are $1.29 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biostem Technologies Inc worth?
The market values Biostem Technologies Inc at about $57.3M (market capitalisation, as of Oct 2, 2026). Per share that is $2.44; our models calculate a fair value of $3.73 per share.
What do the bullish and bearish scenarios say about BSEM?
Our models span a range for Biostem Technologies Inc: cautious scenario $2.25, base $3.73, optimistic $6.05 per share (as of Oct 2, 2026, price $2.44). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BSEM?
Biostem Technologies Inc trades at a price-to-earnings ratio of 2.8 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.73 is built from several models across several years. Other multiples: P/B 1.4, P/S 1.7.
How solid is the balance sheet of Biostem Technologies Inc (BSEM)?
Balance-sheet figures for Biostem Technologies Inc (as of Oct 2, 2026): return on equity −74.7%, debt of 0.00 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is BSEM from its 52-week high?
Biostem Technologies Inc trades at $2.44, about 70% below its 52-week high of $8.20 and 2% above the low of $2.39 (as of Oct 12, 2026). Distance from the high says nothing about value: that is what the fair value of $3.73 is for.
Which stocks are comparable to Biostem Technologies Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biostem Technologies Inc stock attractive at the current price?
The data as of Oct 2, 2026: price $2.44, calculated fair value $3.73 (+53%), Quality Score 63/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BSEM calculated?
We run Biostem Technologies Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.8 % above its aggregate fair value. Biostem Technologies Inc currently trades 35 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biostem Technologies Inc (BSEM)?
The closing price on Oct 12, 2026 was $2.44. Our model-based fair value is $3.73, about +53% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biostem Technologies Inc right now?
The model range is unusually wide ($2.25 to $6.05). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Biostem Technologies Inc
How large is the market capitalisation of Biostem Technologies Inc (BSEM)?
The market capitalisation of Biostem Technologies Inc is $57.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biostem Technologies Inc (BSEM)?
The price-to-sales ratio of Biostem Technologies Inc is 0.29 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biostem Technologies Inc (BSEM)?
Earnings per share at Biostem Technologies Inc are $0.8800 (price ÷ EPS = P/E 2.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biostem Technologies Inc (BSEM)?
The net margin of Biostem Technologies Inc is 10.6% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biostem Technologies Inc (BSEM)?
The return on equity (ROE) of Biostem Technologies Inc is −74.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biostem Technologies Inc (BSEM)?
On an EBIT basis the return on assets of Biostem Technologies Inc is −59.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biostem Technologies Inc (BSEM)?
The operating margin of Biostem Technologies Inc is −106% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biostem Technologies Inc (BSEM)?
Revenue at Biostem Technologies Inc is growing −27.9% versus a year earlier (3y avg +311%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biostem Technologies Inc (BSEM)?
Earnings per share at Biostem Technologies Inc are growing −90.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Biostem Technologies Inc (BSEM) generate?
The free cash flow of Biostem Technologies Inc is $24.1M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Biostem Technologies Inc (BSEM) carry?
The net debt of Biostem Technologies Inc is $4.5M (fiscal year 2023, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Biostem Technologies Inc in the live analysis
One click puts Biostem Technologies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 2, 2026